Low dose dextromethorphan attenuates moderate experimental autoimmune encephalomyelitis by inhibiting NOX2 and reducing peripheral immune cells infiltration in the spinal cord

Olga V. Chechneva, Florian Mayrhofer, Daniel J. Daugherty, David E Pleasure, Jau Shyong Hong, Wenbin Deng

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Dextromethorphan (DM) is a dextrorotary morphinan and a widely used component of cough medicine. Relatively high doses of DM in combination with quinidine are used for the treatment of mood disorders for patients with multiple sclerosis (MS). However, at lower doses, morphinans exert anti-inflammatory activities through the inhibition of NOX2-dependent superoxide production in activated microglia. Here we investigated the effects of high (10mg/kg, i.p., "DM-10") and low (0.1mg/kg, i.p., "DM-0.1") doses of DM on the development and progression of mouse experimental autoimmune encephalomyelitis (EAE), an animal model of MS. We found no protection by high dose DM treatment. Interestingly, a minor late attenuation by low dose DM treatment was seen in severe EAE that was characterized by a chronic disease course and a massive spinal cord infiltration of CD45 + cells including T-lymphocytes, macrophages and neutrophils. Furthermore, in a less severe form of EAE, where lower levels of CD4 + and CD8 + T-cells, Iba1 + microglia/macrophages and no significant infiltration of neutrophils were seen in the spinal cord, the treatment with DM-0.1 was remarkably more beneficial. The effect was the most significant at the peak of disease and was associated with an inhibition of NOX2 expression and a decrease in infiltration of monocytes and lymphocytes into the spinal cord. In addition, chronic treatment with low dose DM resulted in decreased demyelination and reduced axonal loss in the lumbar spinal cord. Our study is the first report to show that low dose DM is effective in treating EAE of moderate severity. Our findings reveal that low dose morphinan DM treatment may represent a new promising protective strategy for treating MS.

Original languageEnglish (US)
Pages (from-to)63-72
Number of pages10
JournalNeurobiology of Disease
Volume44
Issue number1
DOIs
StatePublished - Oct 2011

Fingerprint

Dextromethorphan
Autoimmune Experimental Encephalomyelitis
Spinal Cord
Morphinans
Multiple Sclerosis
Microglia
Macrophages
T-Lymphocytes
Therapeutics
Quinidine
Neutrophil Infiltration
Demyelinating Diseases
Mood Disorders
Cough
Superoxides
Monocytes
Neutrophils
Chronic Disease
Anti-Inflammatory Agents
Animal Models

Keywords

  • Axonal loss
  • CNS infiltration
  • Demyelination
  • EAE
  • Low dose dextromethorphan
  • Microglia
  • NOX2 NADPH oxidase

ASJC Scopus subject areas

  • Neurology

Cite this

Low dose dextromethorphan attenuates moderate experimental autoimmune encephalomyelitis by inhibiting NOX2 and reducing peripheral immune cells infiltration in the spinal cord. / Chechneva, Olga V.; Mayrhofer, Florian; Daugherty, Daniel J.; Pleasure, David E; Hong, Jau Shyong; Deng, Wenbin.

In: Neurobiology of Disease, Vol. 44, No. 1, 10.2011, p. 63-72.

Research output: Contribution to journalArticle

@article{6ec2a78797454581bdcd12e5966b41e8,
title = "Low dose dextromethorphan attenuates moderate experimental autoimmune encephalomyelitis by inhibiting NOX2 and reducing peripheral immune cells infiltration in the spinal cord",
abstract = "Dextromethorphan (DM) is a dextrorotary morphinan and a widely used component of cough medicine. Relatively high doses of DM in combination with quinidine are used for the treatment of mood disorders for patients with multiple sclerosis (MS). However, at lower doses, morphinans exert anti-inflammatory activities through the inhibition of NOX2-dependent superoxide production in activated microglia. Here we investigated the effects of high (10mg/kg, i.p., {"}DM-10{"}) and low (0.1mg/kg, i.p., {"}DM-0.1{"}) doses of DM on the development and progression of mouse experimental autoimmune encephalomyelitis (EAE), an animal model of MS. We found no protection by high dose DM treatment. Interestingly, a minor late attenuation by low dose DM treatment was seen in severe EAE that was characterized by a chronic disease course and a massive spinal cord infiltration of CD45 + cells including T-lymphocytes, macrophages and neutrophils. Furthermore, in a less severe form of EAE, where lower levels of CD4 + and CD8 + T-cells, Iba1 + microglia/macrophages and no significant infiltration of neutrophils were seen in the spinal cord, the treatment with DM-0.1 was remarkably more beneficial. The effect was the most significant at the peak of disease and was associated with an inhibition of NOX2 expression and a decrease in infiltration of monocytes and lymphocytes into the spinal cord. In addition, chronic treatment with low dose DM resulted in decreased demyelination and reduced axonal loss in the lumbar spinal cord. Our study is the first report to show that low dose DM is effective in treating EAE of moderate severity. Our findings reveal that low dose morphinan DM treatment may represent a new promising protective strategy for treating MS.",
keywords = "Axonal loss, CNS infiltration, Demyelination, EAE, Low dose dextromethorphan, Microglia, NOX2 NADPH oxidase",
author = "Chechneva, {Olga V.} and Florian Mayrhofer and Daugherty, {Daniel J.} and Pleasure, {David E} and Hong, {Jau Shyong} and Wenbin Deng",
year = "2011",
month = "10",
doi = "10.1016/j.nbd.2011.06.004",
language = "English (US)",
volume = "44",
pages = "63--72",
journal = "Neurobiology of Disease",
issn = "0969-9961",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Low dose dextromethorphan attenuates moderate experimental autoimmune encephalomyelitis by inhibiting NOX2 and reducing peripheral immune cells infiltration in the spinal cord

AU - Chechneva, Olga V.

AU - Mayrhofer, Florian

AU - Daugherty, Daniel J.

AU - Pleasure, David E

AU - Hong, Jau Shyong

AU - Deng, Wenbin

PY - 2011/10

Y1 - 2011/10

N2 - Dextromethorphan (DM) is a dextrorotary morphinan and a widely used component of cough medicine. Relatively high doses of DM in combination with quinidine are used for the treatment of mood disorders for patients with multiple sclerosis (MS). However, at lower doses, morphinans exert anti-inflammatory activities through the inhibition of NOX2-dependent superoxide production in activated microglia. Here we investigated the effects of high (10mg/kg, i.p., "DM-10") and low (0.1mg/kg, i.p., "DM-0.1") doses of DM on the development and progression of mouse experimental autoimmune encephalomyelitis (EAE), an animal model of MS. We found no protection by high dose DM treatment. Interestingly, a minor late attenuation by low dose DM treatment was seen in severe EAE that was characterized by a chronic disease course and a massive spinal cord infiltration of CD45 + cells including T-lymphocytes, macrophages and neutrophils. Furthermore, in a less severe form of EAE, where lower levels of CD4 + and CD8 + T-cells, Iba1 + microglia/macrophages and no significant infiltration of neutrophils were seen in the spinal cord, the treatment with DM-0.1 was remarkably more beneficial. The effect was the most significant at the peak of disease and was associated with an inhibition of NOX2 expression and a decrease in infiltration of monocytes and lymphocytes into the spinal cord. In addition, chronic treatment with low dose DM resulted in decreased demyelination and reduced axonal loss in the lumbar spinal cord. Our study is the first report to show that low dose DM is effective in treating EAE of moderate severity. Our findings reveal that low dose morphinan DM treatment may represent a new promising protective strategy for treating MS.

AB - Dextromethorphan (DM) is a dextrorotary morphinan and a widely used component of cough medicine. Relatively high doses of DM in combination with quinidine are used for the treatment of mood disorders for patients with multiple sclerosis (MS). However, at lower doses, morphinans exert anti-inflammatory activities through the inhibition of NOX2-dependent superoxide production in activated microglia. Here we investigated the effects of high (10mg/kg, i.p., "DM-10") and low (0.1mg/kg, i.p., "DM-0.1") doses of DM on the development and progression of mouse experimental autoimmune encephalomyelitis (EAE), an animal model of MS. We found no protection by high dose DM treatment. Interestingly, a minor late attenuation by low dose DM treatment was seen in severe EAE that was characterized by a chronic disease course and a massive spinal cord infiltration of CD45 + cells including T-lymphocytes, macrophages and neutrophils. Furthermore, in a less severe form of EAE, where lower levels of CD4 + and CD8 + T-cells, Iba1 + microglia/macrophages and no significant infiltration of neutrophils were seen in the spinal cord, the treatment with DM-0.1 was remarkably more beneficial. The effect was the most significant at the peak of disease and was associated with an inhibition of NOX2 expression and a decrease in infiltration of monocytes and lymphocytes into the spinal cord. In addition, chronic treatment with low dose DM resulted in decreased demyelination and reduced axonal loss in the lumbar spinal cord. Our study is the first report to show that low dose DM is effective in treating EAE of moderate severity. Our findings reveal that low dose morphinan DM treatment may represent a new promising protective strategy for treating MS.

KW - Axonal loss

KW - CNS infiltration

KW - Demyelination

KW - EAE

KW - Low dose dextromethorphan

KW - Microglia

KW - NOX2 NADPH oxidase

UR - http://www.scopus.com/inward/record.url?scp=79961128957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79961128957&partnerID=8YFLogxK

U2 - 10.1016/j.nbd.2011.06.004

DO - 10.1016/j.nbd.2011.06.004

M3 - Article

C2 - 21704706

AN - SCOPUS:79961128957

VL - 44

SP - 63

EP - 72

JO - Neurobiology of Disease

JF - Neurobiology of Disease

SN - 0969-9961

IS - 1

ER -